Latest Conference Articles

Metformin failed to improve invasive disease-free survival or overall survival when used as adjuvant treatment in patients with early breast cancer, irrespective of estrogen or progesterone receptor status.

Tamoxifen May Increase Risk of Secondary Uterine Cancer In Select Patients With Primary Breast Cancer

December 7th 2021, 2:35pm

Patients with primary breast cancer who developed secondary uterine cancer following treatment with tamoxifen may have had disease driven by PI3K-pathway activation.

Fulvestrant/Palbociclib Following AI/Palbociclib Doubles PFS in HR+/HER2- Metastatic Breast Cancer

December 7th 2021, 2:00pm

Patients with hormone receptor–positive, HER2-negative metastatic breast cancer with rising ESR1 mutations previously treated with an aromatase inhibitor plus palbociclib had a doubling of progression-free survival when switched to fulvestrant plus palbociclib before disease progression, according to findings from the phase 3 PADA-1 trial.

Matched Targeted Therapy Improves PFS Through Multigene Sequencing in Metastatic Breast Cancer

December 7th 2021, 2:00pm

Genomic alterations identified through multigene sequencing, classified in the I/II tiers of the ESMO Scale of Actionability of Molecular Targets, and paired with matching targeted therapy led to a significant improvement in progression-free survival vs maintenance chemotherapy in patients with HER2-negative metastatic breast cancer.

Single-Cell Spatial Analysis for Immunotherapy Response Prediction in Early TNBC Shows Promise

December 7th 2021, 2:00pm

ASH Annual Meeting and Exposition

Imaging mass cytometry at the single-cell level showed potential as an immunotherapy response prediction tool in early triple-negative breast cancer.

Liso-cel Significantly Prolongs EFS Over SOC in Second-Line Relapsed/Refractory LBCL

December 3rd 2021, 2:28pm

Lisocabtagene maraleucel significantly prolonged event-free survival and progression-free survival and improved complete responses when used in the second-line treatment of patients with relapsed or refractory large B-cell lymphoma.

Lisocabtagene Maraleucel Displays Durable Remissions in Relapsed/Refractory LBCL

November 29th 2021, 2:13pm

ASH Annual Meeting and Exposition

Lisocabtagene maraleucel demonstrated durable responses and a favorable safety profile in patients with relapsed/refractory large B-cell lymphoma.

Dr. Márquez Rodas on the Preliminary Efficacy of BO-112/Pembrolizumab in Advanced Melanoma

November 23rd 2021, 8:59pm

Iván Márquez Rodas, MD, PhD, discusses the preliminary results of the phase 2 SPOTLIGHT203 trial, which is evaluating the efficacy and safety of BO-112 plus pembrolizumab in patients with advanced melanoma.

Dr. Reiss Binder on Initial Results of a Phase 1 Study of CT-0508 in HER2+ Solid Tumors

November 23rd 2021, 8:55pm

Kim A. Reiss Binder, MD, discusses the initial results of a phase 1 trial, which is evaluating CT-0508 in patients with HER2-overexpressing solid tumors.

Dr. Moutafi on the Results of a Study Evaluating Biomarkers of Resistance in NSCLC

November 19th 2021, 7:59pm

Myrto Moutafi, MD, MSc, discusses the results of a study evaluating biomarkers of resistance in non–small cell lung cancer.

Dr. Nebhan on the Efficacy of Checkpoint Inhibitors in Older Patients With Cancer

November 19th 2021, 7:56pm

Caroline Nebhan, MD, PhD, discusses the efficacy of checkpoint inhibitors in older patients with cancer.

Dr. Wildiers on the Final Results of the AIPAC Trial in HR+/HER2- Metastatic Breast Cancer

November 19th 2021, 7:51pm

Hans Wildiers, MD, medical oncologist, Department of Medical Oncology, full professor, Faculty of Medicine, member, Laboratory of Experimental Oncology, University Hospital Leuven, Leuven, Belgium, discusses the final results of the phase 2b AIPAC trial (NCT02614833) in hormone receptor (HR)–positive, HER2-negative metastatic breast cancer.

Dr. Cheng on Advances With Immunotherapy-Based Combinations in Oncology

November 19th 2021, 7:48pm

Jonathan D. Cheng, MD, discusses advances with immunotherapy-based combinations in oncology.

Dr. Li on the Interim Results of a Phase 1 Trial With Surufatinib in NETs

November 17th 2021, 10:03pm

Daneng Li, MD, discusses the interim analysis results of a phase 1 trial evaluating surufatinib in United States patients with neuroendocrine tumors.

Dr. Reidy-Lagunes on the Results of the SPINET Study by Tumor Subtype in BP-NETs

November 17th 2021, 10:01pm

Diane Reidy-Lagunes, MD, discusses the results of the phase 3 SPINET trial by tumor subtype in bronchopulmonary neuroendocrine tumors.

Surufatinib Shows Comparable HRQoL Vs Placebo in Advanced Neuroendocrine Tumors

November 16th 2021, 6:47pm

Surufatinib demonstrated a comparable health-related quality of life with placebo in patients with advanced neuroendocrine tumors.

Liso-Cel/Ibrutinib Combo Improves Efficacy in Relapsed/Refractory CLL

November 16th 2021, 2:10pm

Concurrent treatment with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia who were receiving lisocabtagene maraleucel led to measurable effects in both CAR+ and endogenous T cells, both of which were linked with improved efficacy.

Prospective Biomarkers of Pembrolizumab Combo Response Show Feasibility in Frontline Advanced NSCLC

November 15th 2021, 8:25pm

T-cell inflamed gene expression profile and tumor mutational burden assessment was found to be a feasible approach to study the clinical activity of 3 pembrolizumab-based combination regimens in treatment-naïve patients with advanced non–small cell lung cancer.

Tidutamab Shows Early Tolerability, Active Immune Profile in Advanced Neuroendocrine Tumors

November 15th 2021, 7:33pm

Tidutamab was found to be well tolerated with a best overall response of stable disease in patients with advanced, well-differentiated neuroendocrine tumors of pancreatic, gastrointestinal, lung and undetermined origin.

Patients with RCC, Melanoma Taking ICIs Can Safely Receive COVID-19 Vaccination

November 15th 2021, 6:58pm